Resistance to PD1/PDL1 checkpoint inhibition
Author:
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference110 articles.
1. Combination cancer immunotherapies tailored to the tumor microenvironment;Smyth;Nat Rev Clin Oncol,2015
2. The future of immune checkpoint therapy;Sharma;Science,2015
3. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer;Topalian;N Engl J Med,2012
4. Acquired resistance to immunotherapy and future challenges;Restifo;Nat Rev Cancer,2016
5. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy;Swaika;Mol Immunol,2015
Cited by 438 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A novel 7-phenoxy-benzimidazole derivative as a potent and orally available BRD4 inhibitor for the treatment of melanoma;Bioorganic & Medicinal Chemistry;2024-10
2. The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies;Future Oncology;2024-09-04
3. Single-cell RNA sequencing analysis reveals the distinct features of colorectal cancer with or without Fusobacterium nucleatum infection in PD-L1 blockade therapy;Heliyon;2024-09
4. Targeting autophagy can synergize the efficacy of immune checkpoint inhibitors against therapeutic resistance: New promising strategy to reinvigorate cancer therapy;Heliyon;2024-09
5. Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/CCL5 mediated M1 macrophage polarization in melanoma;Biomaterials;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3